title: Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma.
abstract: BACKGROUND
  The objective of this phase II trial was to investigate the safety and efficacy of autologous heat shock protein-peptide complex 96 (HSPPC-96) vaccines prepared from tumor specimens of patients with newly diagnosed or previously treated indolent non-Hodgkin lymphoma (NHL).
  
  
  METHODS
  The study was for patients with indolent B-cell NHL with measurable lesions. HSPPC-96 vaccines were prepared from patients' resected tumor specimens and administered as a 25-microg intradermal injection in the absence of disease progression every week for 4 weeks and then every 2 weeks until the vaccine supply was exhausted.
  
  
  RESULTS
  Twenty patients were enrolled in this trial. The median patient age was 59 years. Ten patients had been treated previously (median, 2 regimens; range, 1 to 7). Eighteen (90%) patients had stage III or IV disease. Autologous vaccines were successfully prepared for 17 (85%) patients and all received at least 1 dose. The treatment was very well tolerated. One patient experienced a response with biopsy-proven clearance of the lymphoma cells in 2 of the skin nodules at 3.0 months that lasted for 7.0 months. Eight patients had stable disease for 6.0 to 19.8 months. The median failure-free survival duration in patients who received vaccine therapy was 5.2 months.
  
  
  CONCLUSIONS
  HSPPC-96 can be prepared from tumor specimens for the majority of lymphoma patients, but it had limited efficacy in inducing responses in patients with active diseases. Further studies of HSPPCs, therefore, should be considered in adjuvant settings or in combination with other immunomodulatory agents to assess survival benefit.
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Oki
authors.forename: Peter
authors.initials: P
authors.lastname: McLaughlin
authors.forename: Luis E
authors.initials: LE
authors.lastname: Fayad
authors.forename: Barbara
authors.initials: B
authors.lastname: Pro
authors.forename: Paul F
authors.initials: PF
authors.lastname: Mansfield
authors.forename: Gary L
authors.initials: GL
authors.lastname: Clayman
authors.forename: L Jeffrey
authors.initials: LJ
authors.lastname: Medeiros
authors.forename: Larry W
authors.initials: LW
authors.lastname: Kwak
authors.forename: Pramod K
authors.initials: PK
authors.lastname: Srivastava
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000633:toxicity; D017322:Clinical Trials, Phase II as Topic; D018572:Disease-Free Survival; D005260:Female; D006360:Heat-Shock Proteins / Q000008:administration & dosage* / Q000633:toxicity; D006801:Humans; D007271:Injections, Intradermal; D016393:Lymphoma, B-Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D006360:Heat-Shock Proteins; C484813:vitespin